|
Epigenomics AG / Key word(s): Personnel Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 30-Oct-2023 / 15:49 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 Berlin, Germany, October 30, 2023 – Jens Ravens, Executive Board member of Epigenomics AG (Frankfurt General Standard: ECX1, the “Company”), leaves the Executive Board of the Company with effect as of April 30, 2024, due to the successful transfer of nearly all assets of the Company to New Day Diagnostics LLC. The Supervisory Board will appoint a new Executive Board member in due course and decide on the further composition of the Executive Board. Contact: Investor Relations Note on forward-looking statements This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG’s actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.
End of Inside Information 30-Oct-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
A new $16,000 postpartum depression drug is here. How will insurers handle it?
A much-awaited treatment for postpartum depression, zuranolone, hit the market in December, promising an accessible and fast-acting medication for a debilitating illness.
March 12, 2024